絞り込み

16554

広告

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.

著者 Schoedel KA , Szeto I , Setnik B , Sellers EM , Levy-Cooperman N , Mills C , Etges T , Sommerville K
Epilepsy Behav.2018 Oct 01 ; 88():162-171.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug Enforcement Administration; therefore, it was important to test CBD for human abuse potential.
PMID: 30286443 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード